Joenja (Leniolisib Phosphate) Patent Expiration, LOE Window & CMS Spending
Joenja (Leniolisib Phosphate) by Pharming Technologies Bv: FDA Orange Book core substance LOE 2032-02-19, 0 AB generics, $22.6M 2024 CMS Part D & Medicaid spend, and $45,000 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pharming Technologies Bv |
| FDA Application & Pathway | N217759 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2032-02-19 |
| Last Listed Patent or Exclusivity Date | 2032-02-19 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $22.6M |
| 2024 Medicare Part D Spend | $3.9M |
| 2024 Medicaid Spend | $18.7M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($45,000 intro WAC) |